ASPP2 enhances Oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 3, 2015, Pages 535-543

  Shi, Ying ^a,b   Han, Yue ^c   Xie, Fang ^b   Wang, Anna ^a,b   Feng, Xiaokun ^c   Li, Ning ^a,b   Guo, Hongliang ^c   Chen, Dexi ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Institute of Hepatology   (China)

^c UNIVERSITY OF JINAN   (China)

Author keywords

Apoptosis; ASPP2; Autophagy; Colorectal cancer; P53

Indexed keywords

MUS;

3-METHYLADENINE; ADENINE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; OXALIPLATIN; PLATINUM COMPLEX; PROTEIN P53; SMALL INTERFERING RNA; TP53BP2 PROTEIN, HUMAN;

ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; AUTOPHAGY; BAGG ALBINO MOUSE; COLORECTAL NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; HCT116 CELL LINE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MOUSE; MUTATION; RNA INTERFERENCE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENINE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HCT116 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84923448408     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12435     Document Type: Article

References (32)

1. Chao C, Saito S, Kang J, et al. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J. 2000; 19: 4967-75.
2. Jimenez GS, Nister M, Stommel JM, et al. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat Genet. 2000; 26: 37-43.
3. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002; 2: 594-604.
4. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991; 253: 49-53.
5. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989; 244: 217-21.
6. Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990; 249: 912-5.
7. Vazquez A, Bond EE, Levine AJ, et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 2008; 7: 979-87.
8. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990; 50: 7717-22.
9. Purdie CA, O'Grady J, Piris J, et al. p53 expression in colorectal tumors. Am J Pathol. 1991; 138: 807-13.
10. Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes. Br J Cancer. 2007; 96: 196-200.
11. Lossos IS, Natkunam Y, Levy R, et al. Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma. 2002; 43: 2309-17.
12. Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005; 11: 8623-31.
13. Vives V, Su J, Zhong S, et al. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev. 2006; 20: 1262-7.
14. Chen D, Yu Z, Zhu Z, et al. The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells. Cancer Res. 2006; 66: 3485-94.
15. Wang Y, Wang XD, Lapi E, et al. Autophagic activity dictates the cellular response to oncogenic RAS. Proc Natl Acad Sci U S A. 2012; 109: 13325-30.
16. Kampa KM, Acoba JD, Chen D, et al. Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. Proc Natl Acad Sci U S A. 2009; 106: 4390-5.
17. Ozaki T, Nakagawara A. Role of p53 in Cell Death and Human Cancers. Cancers (Basel). 2011; 3: 994-1013.
18. Wang Y, Godin-Heymann N, Dan Wang X, et al. ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death Differ. 2013; 20: 525-34.
19. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 2001; 8: 781-94.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70.
21. Crighton D, Ryan KM. Splicing DNA-damage responses to tumour cell death. Biochim Biophys Acta. 2004; 1705: 3-15.
22. Beroud C, Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum Mutat. 2003; 21: 176-81.
23. Compton S, Kim C, Griner NB, et al. Mitochondrial dysfunction impairs tumor suppressor p53 expression/function. J Biol Chem. 2011; 286: 20297-312.
24. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992; 70: 523-6.
25. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408: 307-10.
26. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005; 92: 434-44.
27. Staples OD, Steele RJ, Lain S. p53 as a therapeutic target. Surgeon. 2008; 6: 240-3.
28. Mori T, Okamoto H, Takahashi N, et al. Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. FEBS Lett. 2000; 465: 124-8.
29. Czaja MJ, Ding WX, Donohue TM Jr, et al. Functions of autophagy in normal and diseased liver. Autophagy. 2013; 9: 1131-58.
30. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 2005; 12(Suppl 2): 1509-18.
31. Crighton D, Wilkinson S, O'Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell. 2006; 126: 121-34.
32. Kobayashi S, Kajino S, Takahashi N, et al. 53BP2 induces apoptosis through the mitochondrial death pathway. Genes Cells. 2005; 10: 253-60.